Fresenius Kidney Care developed a hepatitis C eradication program that resulted in a 97% cure rate among patients on dialysis who received direct-acting antiviral therapy.
Healio Gastroenterology and Liver Disease spoke with Jeffrey L. Hymes, MD, chief medical officer of Fresenius Kidney Care, about the center’s partnership with the Scripps Clinic Liver Research Consortium to develop a protocol of screening, testing and appropriate treatment application.
“Hepatitis C has been recognized as a problem in dialysis patients for a number of years. The risk for infection from blood transfusions and frequent hospitalizations in the general population are more concentrated in the dialysis population,” Hymes told Healio Gastroenterology and Liver Disease. “The problem was that the treatments that had been available for hepatitis C were really not appropriate for patients on dialysis. Either the treatments were renally excreted or the treatments were particularly toxic and not effective enough.”